Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.55 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.55 |
| ▸ | HTRA1 | Q92743 | 2/20 | 0.54 |
| ▸ | CTSG | P08311 | 2/20 | 0.52 |
| ▸ | CMA1 | P23946 | 2/20 | 0.52 |
| ▸ | FPR2 | P25090 | 1/20 | 0.52 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.52 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.51 |
| ▸ | CCKBR | P32239 | 3/20 | 0.50 |
| ▸ | MME | P08473 | 1/20 | 0.50 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18228818 | 1.00 | ACE (0.55) | ACEITGB3ITGA2BHTRA1CTSG | |
| SCHEMBL18228830 | 0.90 | ACE (0.54) | ACEITGB3ITGA2BCTSGCMA1 | |
| SCHEMBL18228922 | 0.90 | ACE (0.54) | ACEITGB3ITGA2BCTSGCMA1 | |
| SCHEMBL4153095 | 0.88 | ITGB3 (0.65) | ACEITGB3ITGA2BCTSGCMA1 | |
| SCHEMBL4153101 | 0.88 | ITGB3 (0.65) | ACEITGB3ITGA2BCTSGCMA1 | |
| SCHEMBL5458748 | 0.88 | ITGB3 (0.65) | ACEITGB3ITGA2BCTSGCMA1 | |
| SCHEMBL18228675 | 0.84 | FPR2 (0.63) | ACEITGB3ITGA2BCTSGCMA1 | |
| SCHEMBL21391858 | 0.84 | FPR2 (0.63) | ACEITGB3ITGA2BCTSGCMA1 | |
| SCHEMBL31006620 | 0.84 | GPR34 (0.61) | ACEITGB3ITGA2BMMEGPR34 | |
| SCHEMBL9440322 | 0.83 | ITGB3 (0.61) | ACEITGB3ITGA2BCTSGCMA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531653-B | Novel difluoroketoamide derivatives | 豪夫迈·罗氏有限公司 | 2021-10-19 | — | — | CN | disclosed |
| EP-3294718-B1 | NEW DIFLUOROKETAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-04-29 | — | — | EP | disclosed |
| US-10428108-B2 | Difluoroketamide derivatives | HOFFMANN-LA ROCHE INC. (US) | 2019-10-01 | — | — | US | disclosed |
| CN-107531653-A | Novel difluoroketoamide derivatives | 豪夫迈·罗氏有限公司 | 2018-01-02 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428108-B2 | Difluoroketamide derivatives | PRMT9, CDK9, FLT3 | ACE 1622/4885ITGB3 2630/4885ITGA2B 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.